PCM
SGMO

Prelude Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Prelude Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,900
Closed -$44K – 2283
2020
Q2 		$44K Buy
+4,900
New +$45.5K ﹤0.01% 1195
2019
Q2 		– Sell
-100
Closed -$1K – 2094
2019
Q1 		$1K Buy
+100
New +$1.02K ﹤0.01% 1707

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Prelude Capital Management's SGMO Position: Q1 2026 in Review

Prelude Capital Management reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 15% in Q1 2026, selling an estimated $3.78K and leaving 53,779 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Prelude Capital Management first reported a position in SGMO in Q2 2013 and has held it in 21 quarters since. The position peaked at $725K in Q3 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Prelude Capital Management held 53,779 shares of SANGAMO THERAPEUTICS INC worth $13.3K as of Q1 2026.
  • Prelude Capital Management sold 9,496 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $3.78K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1168 holding.
  • Prelude Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 21 quarters since.
  • Prelude Capital Management's SANGAMO THERAPEUTICS INC position peaked at $725K in Q3 2018.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.